È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå : Ä¡·á À¯Çü, ¾àÁ¦ À¯Çü, Åõ¿© °æ·Î, À¯Åë ä³Îº°, ¿¹Ãø(2024-2032³â)
Chemotherapy-Induced Neutropenia Treatment Market - By Treatment Type (G-CSF, Antibiotics, Granulocyte Transfusion, Antifungals), Drug Type (Branded, Biosimilars), Route of administration (Parenteral, Oral), Distribution Channel & Forecast, 2024 - 2032
»óǰÄÚµå : 1518526
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 110 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå ±Ô¸ð´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÂÀÎÀ» ÇâÇÑ À¯¸®ÇÑ ±ÔÁ¦ °æ·Î¿Í ó¹æÀÚ ¹× ȯÀÚ »çÀÌ¿¡¼­ÀÇ ¼ö¿ë È®´ë¿¡ ÀÇÇØ 2024-2032³â¿¡ CAGR 3.7%¸¦ ±â·ÏÇÕ´Ï´Ù.

¾ÏÀ» Æ÷ÇÔÇÑ ¸¸¼ºÁúȯÀÇ È®»êÀº ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î, CDC º¸°í¼­¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â 170¸¸ ¸íÀÌ ¾Ï Áø´ÜÀ» ¹Þ°í 60¸¸ ¸í ÀÌ»óÀÌ »ç¸ÁÇÏ¿© »ç¸Á ¿øÀÎ Áß 2À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á ºñ¿ëÀº Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, 2030³â¿¡´Â 2,400¾ï ´Þ·¯ ÀÌ»ó¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¾Ï ȯÀÚ°¡ ±ÞÁõÇÔ¿¡ µû¶ó È­Çпä¹ýÀÌ Ä¡·áÁ¦·Î »ç¿ëµÇ¸é¼­ È­Çпä¹ý À¯¹ß¼º È£Áß±¸°¨¼ÒÁõ(CIN)ÀÇ °¡´É¼ºÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, CINÀÇ ÇÕ¸®Àû °ü¸®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀÇ ÀáÀç·ÂÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ±âÁ¸ Ä¡·áÁ¦¿¡ ´ëÇÑ ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á Á¢±Ù¼ºÀÌ ³ô°í ºñ¿ë È¿À²ÀûÀΠȣÁß±¸°¨¼ÒÁõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ºÎÀÀÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

È­Çпä¹ý À¯¹ß¼º È£Áß±¸°¨¼ÒÁõ Ä¡·á »ê¾÷Àº Ä¡·á À¯Çü, ¾à¹° À¯Çü, Åõ¿© °æ·Î, À¯Åë ä³Î ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.

¹ÙÀÌ¿À½Ã¹Ð·¯ ºÐ¾ß´Â ±âÁ¸ Ä¡·á¹ý¿¡ ´ëÇÑ ºñ¿ë È¿À²ÀûÀÎ ´ëü ¿ä¹ýÀ» Á¦°øÇÔ¿¡ µû¶ó 2032³â±îÁö ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. È£Áß±¸°¨¼ÒÁõ Ä¡·á¿¡ ¹ÙÀÌ¿À½Ã¹Ð·¯¸¦ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ÀÇ·á ºñ¿ëÀ» ÁÙÀ̸鼭 Ä¡·á ¿ä¹ýÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°è¿¡¼­ ÀÇ·á ÀÎÇÁ¶ó´Â ȯÀÚ Ä¡·áÀÇ ÁúÀ» ¶³¾î¶ß¸®Áö ¾ÊÀ¸¸é¼­µµ ºñ¿ëÀ» Àý°¨ÇÒ Çʿ䰡 ÀÖÀ¸¸ç, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µµÀÔÀº ¾ÈÀü ±âÁØÀ» À¯ÁöÇϸ鼭 °æÁ¦Àû ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ´Â ¸Å·ÂÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

°æ±¸¿ë Ä¡·áÁ¦ ºÎ¹®Àº ÆíÀǼº°ú À¯¿¬¼ºÀ¸·Î ÀÎÇØ 2024-2032³â µ¿¾È ¿Ï¸¸ÇÏ°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. È£Áß±¸°¨¼ÒÁõ Ä¡·á¸¦ À§ÇÑ °æ±¸¿ë ¼Ö·ç¼ÇÀÇ °³¹ß·Î ȯÀÚ Áß½ÉÀÇ Ä¡·á°¡ °¡´ÉÇØÁ® ¿Ü·¡ ¶Ç´Â Áý¿¡¼­ Æí¾ÈÇÏ°Ô Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ¾à¹°Àü´Þ ±â¼úÀÇ Çõ½ÅÀ¸·Î °æ±¸¿ë Á¦Á¦ÀÇ »ýü ÀÌ¿ë·ü°ú ¾àµ¿ÇÐÀÌ °³¼±µÇ¾î ±× »ç¿ëÀÌ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå ±Ô¸ð´Â źźÇÑ ÀÇ·á ÀÎÇÁ¶ó¿Í ³ôÀº ¾Ï ¹ßº´·ü·Î ÀÎÇØ 2024-2032³â °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º¿Í °°Àº ±¹°¡µéÀÌ Á¾¾çÇп¡ ´ëÇÑ ÅõÀÚ¿Í Ã·´Ü Ä¡·á¹ý äÅÃÀ¸·Î »ê¾÷ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ Çù·ÂÀ¸·Î È£Áß±¸°¨¼ÒÁõ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇÏ°í »ó¿ëÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¾Ï Ä¡·á¿¡ ´ëÇÑ Àû±ØÀûÀÎ Á¢±Ù ¹æ½Ä°ú À¯¸®ÇÑ Á¤Ã¥Àº ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¸ñÇÒ ¸¸ÇÑ À§Ä¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Ä¡·á À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¾àÁ¦ À¯Çüº°, 2021-2032³â

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦10Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global chemotherapy-induced neutropenia treatment market size will register 3.7% CAGR during 2024-2032, owing to favorable regulatory pathways for approval of biosimilars and growing acceptance among prescribers and patients.

Prevalence of chronic diseases including cancer is a major growth factor for the market. According to the CDC report, in the US, 1.7 million people are diagnosed with cancer annually, with over 600,000 fatalities, making it the second leading cause of death. The cost of cancer care is continually increasing and is projected to exceed $240 billion by 2030. As the cases of cancer surge worldwide, so does the use of chemotherapy as a treatment modality, increasing the likelihood of chemotherapy-induced neutropenia (CIN). This growing demand for rational management of CIN highlights the viability of innovative treatment options such as biosimilars. By providing cost-effective alternatives to conventional treatments, biosimilars address the growing need for accessible and cost-effective neutropenia treatments, which is driving market growth.

Chemotherapy-induced neutropenia treatment industry is classified based on treatment type, drug type, route of administration, distribution channel, and region.

The biosimilars segment will grow rapidly through 2032, as they offer cost-effective alternative to conventional therapies. The increasing availability of biosimilars for the treatment of neutropenia has given healthcare providers the opportunity to optimize treatment regimens while reducing healthcare costs. Additionally, as healthcare infrastructure worldwide is under increased pressure to contain costs without compromising patient care, the introduction of biosimilars is an attractive solution to lighten the financial burden while maintaining safety standards, which will drive growth in the segment.

The oral formulations segment will grow moderately during 2024-2032, due to the convenience and flexibility. The development of oral solutions to treat neutropenia enable patient-centered treatments so that people can receive treatment on an outpatient basis or even in the comfort of their own home. In addition, innovations in drug delivery techniques have increased the bioavailability and pharmacokinetics of oral formulations, further increasing their use.

Europe chemotherapy-induced neutropenia treatment industry size will grow strongly between 2024 and 2032, due to robust healthcare infrastructure and high incidence of cancer. Countries such as Germany, the United Kingdom and France are leading industry growth, fueled by investments in oncology and the adoption of advanced treatments. In addition, collaboration between pharmaceutical companies and research institutes enables the development & commercialization of new treatments for neutropenia. The region's proactive approach to cancer treatment and favorable policies contribute to its notable position in the global market.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â